bntx-6k_20210622.DOCX.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF JUNE 2021

COMMISSION FILE NUMBER 001-39081

BioNTech SE
(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F Form 40‑F

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7):



DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

 

On June 22, 2021, BioNTech SE (the “Company”) held a virtual Annual General Meeting without the physical presence of shareholders or their proxies. The voting results from the Annual General Meeting are attached hereto as Exhibit 99.1.

 

 



SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

BioNTech SE

 

 

 

 

 

 

 

By:

/s/ Dr. Sierk Poetting

 

 

Name: Dr. Sierk Poetting

 

 

Title:   Chief Financial Officer

Date: June 22, 2021



EXHIBIT INDEX

 

 

Exhibit

Description of Exhibit

 

 

99.1

Voting results of BioNTech Annual General Meeting 2021.

 

 

 

 

 

 

 

 

bntx-ex991_7.htm

Exhibit 99.1

 

BioNTech SE, Mainz, Germany

Annual General Meeting in Munich, Germany, 22 June 2021

 

 

Voting results - Overview - Only the German version is binding

Agenda Item 2Approval of the actions of the Management Board - accepted

 

 

139,683,231Number of shares for which valid votes were cast (= 56.71 % of the registered share capital)

139,665,613

Yes votes

99.99 % of the valid votes cast

17,618

No votes

0.01 % of the valid votes cast

Agenda Item 3Approval of the actions of the Supervisory Board - accepted

 

 

174,869,015Number of shares for which valid votes were cast (= 71.00 % of the registered share capital)

174,546,675

Yes votes

99.82 % of the valid votes cast

322,340

No votes

0.18 % of the valid votes cast

Agenda Item 4Appointment of the auditor for the 2021 financial year - accepted

 

 

179,468,511Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)

179,212,710

Yes votes

99.86 % of the valid votes cast

255,801

No votes

0.14 % of the valid votes cast

Agenda Item 5

Resolution on the revocation of the existing authorized capital and the creation of a new authorized capital (Authorized Capital 2021) against contributions in cash and/or in kind with the possibility of excluding subscription rights and corresponding amendments to the Articles of

Association - accepted

 

 

 

 

179,458,549Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)

172,249,826

Yes votes

95.98 % of the valid votes cast

7,208,723

No votes

4.02 % of the valid votes cast

Agenda Item 6Amendment of the authorization to issue stock options - accepted

 

 

179,451,731Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)

178,976,669

Yes votes

99.74 % of the valid votes cast

475,062

No votes

0.26 % of the valid votes cast

Agenda Item 7

Resolution on the partial revocation and amendment of the current authorization to issue stock options (Stock Option Program 2017/2019) and on the partial revocation of Conditional Capital ESOP 2017/2019 / Resolution on the authorization to issue stock options (Stock Option Program 2021) and on the implementation of a new Conditional Capital 2021 and corresponding

amendments to the Articles of Association - accepted

 

 

 

 

179,449,615Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)

178,569,618

Yes votes

99.51 % of the valid votes cast

879,997

No votes

0.49 % of the valid votes cast

Agenda Item 8

Amendment to the existing authorization to acquire treasury shares and their use, also excluding

subscription rights - accepted

 

 

 

 

179,420,084Number of shares for which valid votes were cast (= 72.84 % of the registered share capital)

178,821,434

Yes votes

99.67 % of the valid votes cast

598,650

No votes

0.33 % of the valid votes cast

Agenda Item 9

Extending the authorization to acquire treasury shares and to use them, also excluding

subscription rights - accepted

 

 

 

 

179,421,159Number of shares for which valid votes were cast (= 72.84 % of the registered share capital)

177,245,311

Yes votes

98.79 % of the valid votes cast

2,175,848

No votes

1.21 % of the valid votes cast


BioNTech SE, Mainz, Germany

Annual General Meeting in Munich, Germany, 22 June 2021

 

 

 

 

Agenda Item 10

Resolution on the approval of the system for the compensation of the members of the

Management Board - accepted

 

 

 

 

179,453,511Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)

178,335,590

Yes votes

99.38 % of the valid votes cast

1,117,921

No votes

0.62 % of the valid votes cast

 


BioNTech SE, Mainz, Germany

Annual General Meeting in Munich, Germany, 22 June 2021

 

 

 

 

Voting results - Overview - Only the German version is binding

Agenda Item 11

Resolution on the compensation and on the compensation system for the members of the

Supervisory Board and an amendment of Sec. 9 para. 6 of the Articles of Association - accepted

 

 

 

 

177,349,170Number of shares for which valid votes were cast (= 72.00 % of the registered share capital)

177,145,624

Yes votes

99.89 % of the valid votes cast

203,546

No votes

0.11 % of the valid votes cast

Agenda Item 12

Resolution on the revocation of the resolution of the Company’s Annual General Meeting of June 26, 2020 (agenda item 8 letter d)) on the consent to the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and JPT Peptide

Technologies GmbH as dependent company - accepted

 

 

 

 

179,452,623Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)

179,428,491

Yes votes

99.99 % of the valid votes cast

24,132

No votes

0.01 % of the valid votes cast

 

Agenda Item 13 a)

Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and JPT Peptide Technologies GmbH as dependent company

 

- accepted

 

 

 

 

 

179,452,355Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)

179,428,811

Yes votes

99.99 % of the valid votes cast

23,544

No votes

0.01 % of the valid votes cast

 

Agenda Item 13 b)

Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company with BioNTech Manufacturing Marburg GmbH as dependent company - accepted

 

 

 

 

 

179,455,727Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)

179,435,690

Yes votes

99.99 % of the valid votes cast

20,037

No votes

0.01 % of the valid votes cast

 

Agenda Item 13 c)

Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and reSano GmbH as dependent company - accepted

 

 

 

 

 

179,453,445Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)

179,432,707

Yes votes

99.99 % of the valid votes cast

20,738

No votes

0.01 % of the valid votes cast